ProCE Banner Activity

Management of Treatment-Experienced Patients With HIV

Text Module

Eric S. Daar, MD, provides an update on current approaches to managing treatment-experienced patients with HIV who have limited antiretroviral treatment options available.

Released: April 07, 2021

Expiration: April 06, 2022

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Atea, GlaxoSmithKline, Gilead Sciences, Merck, and ViiV and funds for research support from Atea, Gilead Sciences, Merck, Novartis, and ViiV.

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.